Acadia Healthcare Company, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 16, 2016, details the completion of a major international expansion and significant capital restructuring by Acadia Healthcare Company, Inc. The filing reports the finalization of the acquisition of Priory Group No. 1 Limited ("Priory"), a leading UK behavioral healthcare provider, alongside the issuance of new senior notes and amendments to existing credit facilities to fund the transaction.
Key Financial Metrics and Capital Structure
- Acquisition Consideration: Total cash consideration of approximately £1.34 billion ($1.94 billion), including £930 million ($1.35 billion) used to repay Priory's existing debt.
- Equity Issuance: Issued 4,033,561 shares of common stock to institutional sellers as part of the acquisition consideration.
- Debt Issuance (Senior Notes): Sold $390 million aggregate principal amount of 6.500% Senior Notes due 2024. Interest is payable semi-annually starting September 1, 2016.
- Debt Issuance (Credit Facilities): Activated a new $955 million incremental Term Loan B facility and added $135 million to the Term Loan A facility.
- Debt Repayment: Used proceeds to pay down the majority of a $300 million revolving credit facility.
- Financial Covenants: Maximum consolidated leverage ratio increased to 6.75x for the first three quarters of 2016, stepping down to 6.25x by year-end. Maximum senior secured leverage ratio set at 3.75x through September 2016, reducing to 3.50x thereafter.
Material Changes Versus Prior Period
The most significant change is the expansion of Acadia's operations into the United Kingdom through the acquisition of Priory, which operates over 300 facilities with approximately 7,100 beds. This transaction fundamentally alters the company's capital structure, significantly increasing total debt load to finance the purchase price and refinance target debt. The company has also amended its credit agreement to accommodate higher leverage ratios consistent with the acquisition.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use remaining proceeds from the new Term Loan facilities for general corporate purposes, including working capital, capital expenditures, and potential future acquisitions or refinancing.
Risks and Contingencies:
- Covenant Compliance: The company is subject to strict financial covenants regarding leverage ratios. Failure to maintain these could trigger an event of default, though the new Term Loan B facility has specific protections regarding covenant maintenance.
- Registration Rights Penalty: If the company fails to file required registration statements for the new notes within specified timelines (360 days for filing, 450 days for effectiveness), the interest rate on the notes will increase by 0.25% per annum, up to a maximum additional 1.0%.
- Redemption Terms: The 6.500% Notes are redeemable at a premium prior to March 1, 2019, and at par or specified prices thereafter.
Investor Verification Checklist
- Verify the exact closing date and final purchase price adjustments for the Priory acquisition in the definitive Sale and Purchase Deed.
- Review the full text of the Indenture (Exhibit 4.1) to understand specific events of default and negative covenants restricting dividends and asset sales.
- Confirm the pro forma financial impact of the acquisition on leverage ratios and liquidity as detailed in the previously filed pro forma information (Exhibit 99.1).
- Monitor the company's ability to meet the 360-day deadline for filing the exchange offer registration statement to avoid interest rate penalties on the new notes.
- Assess the integration risks associated with managing a UK-based entity with 7,100 beds and different regulatory environments.